Incyte earnings forcast
WebFeb 7, 2024 · Incyte (INCY) Earnings Dates & Reports On this page, you can find detailed information about the financial performance of Incyte, including the latest Incyte earnings … WebApr 3, 2024 · We forecast Incyte stock performance using neural networks based on historical data on Incyte stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. ... It uses the current share price and divides it by the total earnings per share for the last 12 months. Forward PE: 14.95
Incyte earnings forcast
Did you know?
WebForecasts Financials Shareholders Competitors Stock Price Forecast The 16 analysts offering 12-month price forecasts for Incyte Corp have a median target of 88.50, with a … WebApr 10, 2024 · Incyte Corp Stock Forecast, Predictions & Price Target Add to Watchlist Overview Forecast Earnings Dividend Ownership Analyst price target for INCY All Analysts …
WebApr 15, 2024 · Incyte currently has a consensus price target of $85.43, suggesting a potential upside of 14.67%. MaxCyte has a consensus price target of $10.50, suggesting a …
WebApr 10, 2024 · Incyte is forecasted to grow earnings and revenue by 29.0% and 10.6% per annum respectively. EPS and ROE are also expected to grow by 28.0% and 20.0% per year … WebMar 20, 2024 · See the latest earnings results for INCY. Explore Incyte Corp.'s earnings history, its beat/miss ratio and outlook for next earnings reports.
WebApr 11, 2024 · The company has a 50 day moving average of $76.33 and a 200-day moving average of $76.86. Incyte Co. has a 1-year low of $65.07 and a 1-year high of $86.29. Gilead Sciences: Now is Not the Time to Get Sticker Shock; Incyte (NASDAQ:INCY - Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical …
WebApr 15, 2024 · Incyte's quarterly revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts forecast that Incyte Co. will post 3.29 earnings per share for the current year. Incyte Profile . Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. the space project manchesterWebAug 4, 2024 · Incyte (INCY) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.75 per share a year ago. These... the space prahranWebApr 10, 2024 · We forecast Incyte stock performance using neural networks based on historical data on Incyte stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. ... It uses the current share price and divides it by the total earnings per share for the last 12 months. Forward PE: 14.95 the space policeWebApr 12, 2024 · Incyte ( NASDAQ:INCY – Get Rating) last released its earnings results on Tuesday, February 7th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. Incyte had a return on equity of 11.45% and a net margin of 10.03%. the space projectWebApr 12, 2024 · INCY: Incyte Detailed Earnings Estimate. Get the latest Detailed Estimate from Zacks Investment Research. INCY: Incyte - Detailed Earnings Estimates - Zacks.com mysharkvertex.comWebApr 11, 2024 · Incyte Trading Down 2.1 %. INCY stock opened at $73.93 on Tuesday. The company has a market capitalization of $16.48 billion, a price-to-earnings ratio of 48.64, a PEG ratio of 3.28 and a beta of ... mysharplightWebApr 12, 2024 · Zacks Consensus Estimate. 0.73. 0.93. 3.99. 5.27. Earnings ESP. More Info. Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best ... the space prezzi